On April 23, ATOS stock was up nearly 30% ahead of today’s presentation by Atossa Genetics’ CEO Steven Quay at the Precision: Breast Cancer World R&D Summit in Boston. It’s now the day of the presentation, and yet, ATOS stock ended the day down nearly 10%.
Here’s what we know.
ATOS Stock Closes Down Nearly 10%Today, at the Precision: Breast Cancer World R&D Summit, Atossa Genetics (NASDAQ:ATOS) CEO provided an update on the company’s clinical programs. First, Quay discussed its Phase 2 clinical study of topical Endoxifen. Then, the CEO addressed its recently ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.